PubMed:23846820 JSONTXT

{"project":"Allie","denotations":[{"id":"SS1_23846820_0_0","span":{"begin":126,"end":151},"obj":"expanded"},{"id":"SS2_23846820_0_0","span":{"begin":153,"end":157},"obj":"abbr"},{"id":"SS1_23846820_2_0","span":{"begin":259,"end":284},"obj":"expanded"},{"id":"SS2_23846820_2_0","span":{"begin":286,"end":290},"obj":"abbr"},{"id":"SS1_23846820_11_0","span":{"begin":1137,"end":1152},"obj":"expanded"},{"id":"SS2_23846820_11_0","span":{"begin":1154,"end":1157},"obj":"abbr"}],"relations":[{"id":"AE1_23846820_0_0","pred":"abbreviatedTo","subj":"SS1_23846820_0_0","obj":"SS2_23846820_0_0"},{"id":"AE1_23846820_2_0","pred":"abbreviatedTo","subj":"SS1_23846820_2_0","obj":"SS2_23846820_2_0"},{"id":"AE1_23846820_11_0","pred":"abbreviatedTo","subj":"SS1_23846820_11_0","obj":"SS2_23846820_11_0"}],"text":"Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.\nCONTEXT: To improve the treatment outcomes in women with polycystic ovary syndrome (PCOS), various drugs like glitazones, oral contraceptive pills, or antiandrogens have been combined with metformin.\nOBJECTIVE: The aim of the study was to compare the efficacy of the combination of low-dose spironolactone and metformin with either drug alone in the management of women with PCOS.\nDESIGN AND SETTING: The present study was an open-label, randomized study conducted at a tertiary care referral center.\nPATIENTS AND INTERVENTION: Of 204 women who met the 2006 Androgen Excess-PCOS criteria for PCOS, 198 were randomized into 3 equal groups to receive metformin (1000 mg/d), low-dose spironolactone (50 mg/d), or a combination of both drugs for a period of 6 months. A total of 169 subjects (n = 56 metformin, 51 spironolactone, 62 combination) completed the study.\nMAIN OUTCOME MEASURES: Menstrual cycle pattern, Ferriman-Gallwey score, body mass index (BMI), waist-hip ratio, blood pressure, LH, FSH, total T, glucose and insulin sensitivity indices were measured at baseline (0 mo) and 3 and 6 months after the intervention. Recording of adverse events and drug compliance was assessed at each of the visits.\nRESULTS: The 3 groups had comparable mean age and BMI at baseline. By 6 months, menstrual cycles/y increased, whereas Ferriman-Gallwey score, serum total T, and area under the curve-glucose and -insulin decreased significantly (P \u003c .05) in the combination group as compared to either drug alone. There was no significant change in body weight, BMI, waist-hip ratio, and blood pressure in any of the 3 groups. The combination group had better compliance than either drug alone, and the adverse event rate was not higher.\nCONCLUSION: The combination of low-dose spironolactone with metformin seems superior to either drug alone in terms of clinical benefits and compliance in women with PCOS."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":259,"end":275},"obj":"HP_0000147"}],"text":"Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.\nCONTEXT: To improve the treatment outcomes in women with polycystic ovary syndrome (PCOS), various drugs like glitazones, oral contraceptive pills, or antiandrogens have been combined with metformin.\nOBJECTIVE: The aim of the study was to compare the efficacy of the combination of low-dose spironolactone and metformin with either drug alone in the management of women with PCOS.\nDESIGN AND SETTING: The present study was an open-label, randomized study conducted at a tertiary care referral center.\nPATIENTS AND INTERVENTION: Of 204 women who met the 2006 Androgen Excess-PCOS criteria for PCOS, 198 were randomized into 3 equal groups to receive metformin (1000 mg/d), low-dose spironolactone (50 mg/d), or a combination of both drugs for a period of 6 months. A total of 169 subjects (n = 56 metformin, 51 spironolactone, 62 combination) completed the study.\nMAIN OUTCOME MEASURES: Menstrual cycle pattern, Ferriman-Gallwey score, body mass index (BMI), waist-hip ratio, blood pressure, LH, FSH, total T, glucose and insulin sensitivity indices were measured at baseline (0 mo) and 3 and 6 months after the intervention. Recording of adverse events and drug compliance was assessed at each of the visits.\nRESULTS: The 3 groups had comparable mean age and BMI at baseline. By 6 months, menstrual cycles/y increased, whereas Ferriman-Gallwey score, serum total T, and area under the curve-glucose and -insulin decreased significantly (P \u003c .05) in the combination group as compared to either drug alone. There was no significant change in body weight, BMI, waist-hip ratio, and blood pressure in any of the 3 groups. The combination group had better compliance than either drug alone, and the adverse event rate was not higher.\nCONCLUSION: The combination of low-dose spironolactone with metformin seems superior to either drug alone in terms of clinical benefits and compliance in women with PCOS."}

{"project":"chenxin_473849_800","denotations":[{"id":"T2","span":{"begin":286,"end":290},"obj":"DP"},{"id":"T3","span":{"begin":153,"end":157},"obj":"DP"},{"id":"T4","span":{"begin":577,"end":581},"obj":"DP"},{"id":"T5","span":{"begin":776,"end":780},"obj":"DP"},{"id":"T6","span":{"begin":794,"end":798},"obj":"DP"},{"id":"T7","span":{"begin":2096,"end":2100},"obj":"DP"},{"id":"T8","span":{"begin":126,"end":151},"obj":"DP"},{"id":"T9","span":{"begin":259,"end":284},"obj":"DP"},{"id":"T10","span":{"begin":493,"end":507},"obj":"CI"},{"id":"T11","span":{"begin":30,"end":44},"obj":"CI"},{"id":"T12","span":{"begin":883,"end":897},"obj":"CI"},{"id":"T13","span":{"begin":1012,"end":1026},"obj":"CI"},{"id":"T14","span":{"begin":1971,"end":1985},"obj":"CI"},{"id":"T15","span":{"begin":512,"end":521},"obj":"CI"},{"id":"T16","span":{"begin":49,"end":58},"obj":"CI"},{"id":"T17","span":{"begin":391,"end":400},"obj":"CI"},{"id":"T18","span":{"begin":851,"end":860},"obj":"CI"},{"id":"T19","span":{"begin":998,"end":1007},"obj":"CI"},{"id":"T20","span":{"begin":1991,"end":2000},"obj":"CI"}],"text":"Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.\nCONTEXT: To improve the treatment outcomes in women with polycystic ovary syndrome (PCOS), various drugs like glitazones, oral contraceptive pills, or antiandrogens have been combined with metformin.\nOBJECTIVE: The aim of the study was to compare the efficacy of the combination of low-dose spironolactone and metformin with either drug alone in the management of women with PCOS.\nDESIGN AND SETTING: The present study was an open-label, randomized study conducted at a tertiary care referral center.\nPATIENTS AND INTERVENTION: Of 204 women who met the 2006 Androgen Excess-PCOS criteria for PCOS, 198 were randomized into 3 equal groups to receive metformin (1000 mg/d), low-dose spironolactone (50 mg/d), or a combination of both drugs for a period of 6 months. A total of 169 subjects (n = 56 metformin, 51 spironolactone, 62 combination) completed the study.\nMAIN OUTCOME MEASURES: Menstrual cycle pattern, Ferriman-Gallwey score, body mass index (BMI), waist-hip ratio, blood pressure, LH, FSH, total T, glucose and insulin sensitivity indices were measured at baseline (0 mo) and 3 and 6 months after the intervention. Recording of adverse events and drug compliance was assessed at each of the visits.\nRESULTS: The 3 groups had comparable mean age and BMI at baseline. By 6 months, menstrual cycles/y increased, whereas Ferriman-Gallwey score, serum total T, and area under the curve-glucose and -insulin decreased significantly (P \u003c .05) in the combination group as compared to either drug alone. There was no significant change in body weight, BMI, waist-hip ratio, and blood pressure in any of the 3 groups. The combination group had better compliance than either drug alone, and the adverse event rate was not higher.\nCONCLUSION: The combination of low-dose spironolactone with metformin seems superior to either drug alone in terms of clinical benefits and compliance in women with PCOS."}

{"project":"Zierdiyeerkenaili_800_3","denotations":[{"id":"T1","span":{"begin":30,"end":44},"obj":"CI"},{"id":"T2","span":{"begin":493,"end":507},"obj":"CI"},{"id":"T3","span":{"begin":883,"end":897},"obj":"CI"},{"id":"T4","span":{"begin":1012,"end":1026},"obj":"CI"},{"id":"T5","span":{"begin":1971,"end":1985},"obj":"CI"},{"id":"T6","span":{"begin":49,"end":58},"obj":"CI"},{"id":"T7","span":{"begin":391,"end":400},"obj":"CI"},{"id":"T8","span":{"begin":512,"end":521},"obj":"CI"},{"id":"T9","span":{"begin":851,"end":860},"obj":"CI"},{"id":"T10","span":{"begin":998,"end":1007},"obj":"CI"},{"id":"T11","span":{"begin":1991,"end":2000},"obj":"CI"},{"id":"T12","span":{"begin":286,"end":290},"obj":"DP"},{"id":"T13","span":{"begin":153,"end":157},"obj":"DP"},{"id":"T14","span":{"begin":577,"end":581},"obj":"DP"},{"id":"T15","span":{"begin":776,"end":780},"obj":"DP"},{"id":"T16","span":{"begin":794,"end":798},"obj":"DP"},{"id":"T17","span":{"begin":2096,"end":2100},"obj":"DP"},{"id":"T18","span":{"begin":259,"end":284},"obj":"DP"},{"id":"T19","span":{"begin":126,"end":151},"obj":"DP"}],"text":"Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.\nCONTEXT: To improve the treatment outcomes in women with polycystic ovary syndrome (PCOS), various drugs like glitazones, oral contraceptive pills, or antiandrogens have been combined with metformin.\nOBJECTIVE: The aim of the study was to compare the efficacy of the combination of low-dose spironolactone and metformin with either drug alone in the management of women with PCOS.\nDESIGN AND SETTING: The present study was an open-label, randomized study conducted at a tertiary care referral center.\nPATIENTS AND INTERVENTION: Of 204 women who met the 2006 Androgen Excess-PCOS criteria for PCOS, 198 were randomized into 3 equal groups to receive metformin (1000 mg/d), low-dose spironolactone (50 mg/d), or a combination of both drugs for a period of 6 months. A total of 169 subjects (n = 56 metformin, 51 spironolactone, 62 combination) completed the study.\nMAIN OUTCOME MEASURES: Menstrual cycle pattern, Ferriman-Gallwey score, body mass index (BMI), waist-hip ratio, blood pressure, LH, FSH, total T, glucose and insulin sensitivity indices were measured at baseline (0 mo) and 3 and 6 months after the intervention. Recording of adverse events and drug compliance was assessed at each of the visits.\nRESULTS: The 3 groups had comparable mean age and BMI at baseline. By 6 months, menstrual cycles/y increased, whereas Ferriman-Gallwey score, serum total T, and area under the curve-glucose and -insulin decreased significantly (P \u003c .05) in the combination group as compared to either drug alone. There was no significant change in body weight, BMI, waist-hip ratio, and blood pressure in any of the 3 groups. The combination group had better compliance than either drug alone, and the adverse event rate was not higher.\nCONCLUSION: The combination of low-dose spironolactone with metformin seems superior to either drug alone in terms of clinical benefits and compliance in women with PCOS."}

{"project":"yaoziqian_800_3","denotations":[{"id":"T1","span":{"begin":126,"end":151},"obj":"DP"},{"id":"T2","span":{"begin":153,"end":157},"obj":"DP"},{"id":"T3","span":{"begin":259,"end":284},"obj":"DP"},{"id":"T4","span":{"begin":286,"end":290},"obj":"DP"},{"id":"T5","span":{"begin":493,"end":507},"obj":"CI"},{"id":"T6","span":{"begin":512,"end":521},"obj":"CI"},{"id":"T7","span":{"begin":30,"end":44},"obj":"CI"},{"id":"T8","span":{"begin":49,"end":58},"obj":"CI"},{"id":"T9","span":{"begin":577,"end":581},"obj":"DP"},{"id":"T10","span":{"begin":391,"end":400},"obj":"CI"},{"id":"T11","span":{"begin":776,"end":780},"obj":"DP"},{"id":"T12","span":{"begin":794,"end":798},"obj":"DP"},{"id":"T13","span":{"begin":851,"end":860},"obj":"CI"},{"id":"T14","span":{"begin":883,"end":897},"obj":"CI"},{"id":"T15","span":{"begin":998,"end":1007},"obj":"CI"},{"id":"T16","span":{"begin":1012,"end":1026},"obj":"CI"},{"id":"T17","span":{"begin":1971,"end":1985},"obj":"CI"},{"id":"T18","span":{"begin":1991,"end":2000},"obj":"CI"},{"id":"T19","span":{"begin":2096,"end":2100},"obj":"DP"}],"text":"Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.\nCONTEXT: To improve the treatment outcomes in women with polycystic ovary syndrome (PCOS), various drugs like glitazones, oral contraceptive pills, or antiandrogens have been combined with metformin.\nOBJECTIVE: The aim of the study was to compare the efficacy of the combination of low-dose spironolactone and metformin with either drug alone in the management of women with PCOS.\nDESIGN AND SETTING: The present study was an open-label, randomized study conducted at a tertiary care referral center.\nPATIENTS AND INTERVENTION: Of 204 women who met the 2006 Androgen Excess-PCOS criteria for PCOS, 198 were randomized into 3 equal groups to receive metformin (1000 mg/d), low-dose spironolactone (50 mg/d), or a combination of both drugs for a period of 6 months. A total of 169 subjects (n = 56 metformin, 51 spironolactone, 62 combination) completed the study.\nMAIN OUTCOME MEASURES: Menstrual cycle pattern, Ferriman-Gallwey score, body mass index (BMI), waist-hip ratio, blood pressure, LH, FSH, total T, glucose and insulin sensitivity indices were measured at baseline (0 mo) and 3 and 6 months after the intervention. Recording of adverse events and drug compliance was assessed at each of the visits.\nRESULTS: The 3 groups had comparable mean age and BMI at baseline. By 6 months, menstrual cycles/y increased, whereas Ferriman-Gallwey score, serum total T, and area under the curve-glucose and -insulin decreased significantly (P \u003c .05) in the combination group as compared to either drug alone. There was no significant change in body weight, BMI, waist-hip ratio, and blood pressure in any of the 3 groups. The combination group had better compliance than either drug alone, and the adverse event rate was not higher.\nCONCLUSION: The combination of low-dose spironolactone with metformin seems superior to either drug alone in terms of clinical benefits and compliance in women with PCOS."}